Johnson & Johnson (NYSE:JNJ) Shares Acquired by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich raised its stake in Johnson & Johnson (NYSE:JNJ) by 2.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,449,009 shares of the company’s stock after buying an additional 50,348 shares during the period. Johnson & Johnson comprises about 2.0% of Bank Julius Baer & Co. Ltd Zurich’s portfolio, making the stock its 9th biggest position. Bank Julius Baer & Co. Ltd Zurich’s holdings in Johnson & Johnson were worth $383,858,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. LaFleur & Godfrey LLC boosted its position in shares of Johnson & Johnson by 4.9% during the 3rd quarter. LaFleur & Godfrey LLC now owns 118,918 shares of the company’s stock valued at $18,521,000 after purchasing an additional 5,585 shares in the last quarter. Hanlon Investment Management Inc. boosted its position in shares of Johnson & Johnson by 46.3% during the 3rd quarter. Hanlon Investment Management Inc. now owns 2,081 shares of the company’s stock valued at $324,000 after purchasing an additional 659 shares in the last quarter. Kessler Investment Group LLC boosted its position in shares of Johnson & Johnson by 1.9% during the 3rd quarter. Kessler Investment Group LLC now owns 52,455 shares of the company’s stock valued at $8,170,000 after purchasing an additional 974 shares in the last quarter. Proficio Capital Partners LLC boosted its position in shares of Johnson & Johnson by 1.5% during the 3rd quarter. Proficio Capital Partners LLC now owns 21,097 shares of the company’s stock valued at $3,286,000 after purchasing an additional 306 shares in the last quarter. Finally, Capital Advisory Group Advisory Services LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter valued at about $1,260,000. Institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

JNJ has been the topic of several research analyst reports. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and upped their target price for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Morgan Stanley dropped their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 17th. Bank of America dropped their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Monday, April 15th. Finally, Raymond James upped their price target on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $175.86.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $144.61 on Wednesday. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. The company has a market cap of $348.48 billion, a PE ratio of 9.02, a price-to-earnings-growth ratio of 2.42 and a beta of 0.53. The business has a 50 day moving average price of $154.80 and a 200-day moving average price of $155.14. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. The company had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. Johnson & Johnson’s revenue was up 2.3% on a year-over-year basis. During the same period last year, the business posted $2.68 earnings per share. Equities analysts anticipate that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.43%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend is Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 29.68%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.